logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan

Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L,  et al.
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...
Journal Article
|
Research

Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis

Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H,  et al.
2020-03-01 • Lancet Global Health
2020-03-01 • Lancet Global Health
BACKGROUND
The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known ...
Journal Article
|
Commentary

Leaving no one behind: Towards equitable global elimination of hepatitis C

Dahl EH, Zahid H, Aslam K, Jafri W
2020-03-14 • Journal of Global Health
2020-03-14 • Journal of Global Health
Journal Article
|
Case Report/Series

DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series

Zahid H, Aslam K, Dahl EH, Abbassi W, Adan S,  et al.
2022-05-23 • Oxford Medical Case Reports
2022-05-23 • Oxford Medical Case Reports
Globally, 58 million people are living with hepatitis C virus (HCV) infection and 1.5 million new patients are infected every year. The advent of direct acting antivirals (DAAs) has revo...